专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07390311B2 Delivery of a sympatholytic cardiovascular agent to the central nervous system 有权
标题翻译：交配性心血管药物向中枢神经系统递送
公开(公告)号：US07390311B2
公开(公告)日：2008-06-24
申请号：US10903599
申请日：2004-07-30
申请人： Keith R. Hildebrand , Michael R. Ujhelyi , Xiaohong Zhou , Daniel C. Sigg , Linda M. Page
发明人： Keith R. Hildebrand , Michael R. Ujhelyi , Xiaohong Zhou , Daniel C. Sigg , Linda M. Page
IPC分类号： A61M31/00
CPC分类号： A61M5/142 , A61M5/14276 , A61M5/1723 , A61M2005/14208 , A61M2205/3523 , A61M2230/00 , A61M2230/04 , A61M2230/63 , A61N1/3962
摘要： A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine).
摘要翻译：由药物输送泵递送至中枢神经系统部位的交感神经心血管药物以缓解急性或慢性心脏损伤或心脏功能受损的症状。药物输送泵可以是外部或植入式输液泵（IIP），其与延伸到现场的药物输注导管结合。患者活化剂可以命令递送剂量和/或与传感器耦合的可植入心脏监测器（IHM）可以检测与心脏损伤相关的生理参数或心脏功能受损并触发剂量递送。 IIP和IHM可以组合成单个可植入医疗设备（IMD），或者可以构成通过任何已知的通信机制进行通信的单独IMD。交感神经心血管药物是由α-肾上腺素能激动剂和α2-肾上腺素能激动剂（例如可乐定，对氨基可乐定，胍苯胺，利脒，替扎尼定，莫索尼定，甲基多巴，甲苯噻嗪，胍法西汀，脱甲基丸，美托咪定和右美托咪定）。

2. 发明申请

US20080228133A1 DELIVERY OF A SYMPATHOLYTIC CARDIOVASCULAR AGENT TO THE CENTRAL NERVOUS SYSTEM 有权
标题翻译：向中央神经系统递送病理性心脏血管代谢
公开(公告)号：US20080228133A1
公开(公告)日：2008-09-18
申请号：US12128046
申请日：2008-05-28
申请人： KEITH R. HILDEBRAND , Michael R. Ujhelyi , Xiaohong Zhou , Daniel C. Sigg , Linda M. Page
发明人： KEITH R. HILDEBRAND , Michael R. Ujhelyi , Xiaohong Zhou , Daniel C. Sigg , Linda M. Page
IPC分类号： A61M31/00
CPC分类号： A61M5/142 , A61M5/14276 , A61M5/1723 , A61M2005/14208 , A61M2205/3523 , A61M2230/00 , A61M2230/04 , A61M2230/63 , A61N1/3962
摘要： A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine).
摘要翻译：由药物输送泵递送至中枢神经系统部位的交感神经心血管药物以缓解急性或慢性心脏损伤或心脏功能受损的症状。药物输送泵可以是外部或植入式输液泵（IIP），其与延伸到现场的药物输注导管结合。患者活化剂可以命令递送剂量和/或与传感器耦合的可植入心脏监测器（IHM）可以检测与心脏损伤相关的生理参数或心脏功能受损并触发剂量递送。 IIP和IHM可以组合成单个可植入医疗设备（IMD），或者可以构成通过任何已知的通信机制进行通信的单独IMD。交感神经心血管药剂是由α-肾上腺素能激动剂和α2-肾上腺素能激动剂（例如可乐定，对氨基可乐定，胍苯胺，利脒，替扎尼定，莫索尼定，甲基多巴，甲苯噻嗪，胍法西林，美托洛尼，美托咪定和右美托咪定）。

3. 发明授权

US08348884B2 Delivery of a sympatholytic cardiovascular agent to the central nervous system 有权
标题翻译：交配性心血管药物向中枢神经系统递送
公开(公告)号：US08348884B2
公开(公告)日：2013-01-08
申请号：US12128046
申请日：2008-05-28
申请人： Keith R. Hildebrand , Michael R. Ujhelyi , Xiaohong Zhou , Daniel C. Sigg , Linda M. Page
发明人： Keith R. Hildebrand , Michael R. Ujhelyi , Xiaohong Zhou , Daniel C. Sigg , Linda M. Page
IPC分类号： A61M31/00
CPC分类号： A61M5/142 , A61M5/14276 , A61M5/1723 , A61M2005/14208 , A61M2205/3523 , A61M2230/00 , A61M2230/04 , A61M2230/63 , A61N1/3962
摘要： A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine).
摘要翻译：由药物输送泵递送至中枢神经系统部位的交感神经心血管药物以缓解急性或慢性心脏损伤或心脏功能受损的症状。药物输送泵可以是外部或植入式输液泵（IIP），其与延伸到现场的药物输注导管结合。患者活化剂可以命令递送剂量和/或与传感器耦合的可植入心脏监测器（IHM）可以检测与心脏损伤相关的生理参数或心脏功能受损并触发剂量递送。 IIP和IHM可以组合成单个可植入医疗设备（IMD），或者可以构成通过任何已知的通信机制进行通信的单独IMD。交感神经心血管药物是由α-肾上腺素能激动剂和α2-肾上腺素能激动剂（例如可乐定，对氨基可乐定，胍苯胺，利脒，替扎尼定，莫索尼定，甲基多巴，甲苯噻嗪，胍法西汀，脱甲基丸，美托咪定和右美托咪定）。

4. 发明授权

US07232435B2 Delivery of a sympatholytic cardiovascular agent to the central nervous system to counter heart failure and pathologies associated with heart failure 有权
标题翻译：向中枢神经系统递送交感神经心血管药物以对抗心力衰竭和与心力衰竭相关的病理
公开(公告)号：US07232435B2
公开(公告)日：2007-06-19
申请号：US10773965
申请日：2004-02-06
申请人： Keith R. Hildebrand , Michael R. Ujhelyi , Xiaohong Zhou , Daniel C. Sigg , Linda M. Page
发明人： Keith R. Hildebrand , Michael R. Ujhelyi , Xiaohong Zhou , Daniel C. Sigg , Linda M. Page
IPC分类号： A61K9/22
CPC分类号： A61M5/142 , A61M5/14276 , A61M5/1723 , A61M2005/14208 , A61M2205/3523 , A61M2230/00 , A61M2230/04 , A61M2230/63 , A61N1/3962
摘要： A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms and otherwise treat heart failure (HF) and pathologies associated with HF. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with HF (or pathologies associated with HF) and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist, e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine.
摘要翻译：由药物输送泵递送至中枢神经系统部位的交感神经心血管药物以缓解症状，另外治疗与HF有关的心力衰竭（HF）和病理学。药物输送泵可以是外部或植入式输液泵（IIP），其与延伸到现场的药物输注导管结合。患者活化剂可以命令递送剂量和/或与传感器耦合的可植入心脏监测器（IHM）可以检测与HF相关的生理学参数（或与HF相关的病理学）和触发剂量递送。 IIP和IHM可以组合成单个可植入医疗设备（IMD），或者可以构成通过任何已知的通信机制进行通信的单独IMD。交感神经心血管药物是由α-肾上腺素能激动剂和α2-肾上腺素能激动剂组成的组之一，例如可乐定，对氨基可乐定，胍苯胺，利脒，替扎尼定，莫西康定，甲基多巴，甲苯噻嗪，胍法辛，右美托咪定。

5. 发明授权

US07169812B2 Process for producing injectable gabapentin compositions 有权
标题翻译：生产可注射加巴喷丁组合物的方法
公开(公告)号：US07169812B2
公开(公告)日：2007-01-30
申请号：US10808113
申请日：2004-03-24
申请人： Keith R. Hildebrand , Linda M. Page , Deanna S. Lane , Dennis D. Elsberry , David A. Clarahan , Jayantha H. Ratnayake
发明人： Keith R. Hildebrand , Linda M. Page , Deanna S. Lane , Dennis D. Elsberry , David A. Clarahan , Jayantha H. Ratnayake
IPC分类号： A61K31/195
CPC分类号： A61K31/52 , A61K9/0019 , A61K9/0085 , A61K31/195 , A61L2/0017 , A61L2/0023 , A61M5/14276 , A61M2202/0464 , A61M2210/0693
摘要： Injectable compositions containing gabapentin and processes for preparing sterile injectable compositions containing gabapentin are discussed. The process includes subjecting the compositions to heat. Heating results in increased production of gabapentin lactam, which has previously been shown to be toxic. Surprisingly, heated injectable compositions containing gabapentin are found to be non-toxic when administered intrathecally. Thus, heating for the purposes of sterilization or to assure sterility provides a viable option in the production of injectable compositions containing gabapentin.
摘要翻译：讨论了含有加巴喷丁的可注射组合物和制备含有加巴喷丁的无菌可注射组合物的方法。该方法包括使组合物加热。加热导致加巴喷丁内酰胺的生产增加，其先前已被证明是有毒的。令人惊奇的是，发现含有加巴喷丁的加热可注射组合物在鞘内施用时是无毒的。因此，用于灭菌或确保无菌的加热为生产含有加巴喷丁的可注射组合物提供了可行的选择。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式